Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

ANCA Associated Vasculitis Clinical Trials

9 recruiting trials for ANCA Associated Vasculitis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
0
Phase 3 Trials
8
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT06285279

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval)...

Sponsor: Nanjing University School of MedicineEnrolling: 241 location
RECRUITINGNCT06462768

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage...

Sponsor: CHU de ReimsEnrolling: 2601 location
RECRUITINGPhase 4NCT05965284

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with...

Sponsor: Chinese SLE Treatment And Research GroupEnrolling: 401 location
RECRUITINGNCT06508346

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset refractory ANCA-Associated...

Sponsor: The Children's Hospital of Zhejiang University School of MedicineEnrolling: 121 location
RECRUITINGNCT04664465

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid...

Sponsor: University Hospital, BrestEnrolling: 30011 locations
RECRUITINGEarly Phase 1NCT07203404

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune...

Sponsor: Nanjing Bioheng Biotech Co., Ltd.Enrolling: 841 location
RECRUITINGNCT06277427

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the...

Sponsor: Lingli DongEnrolling: 241 location
RECRUITINGPhase 4NCT05962840

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to investigate the remission rate of patients treated...

Sponsor: Chinese SLE Treatment And Research GroupEnrolling: 401 location
RECRUITINGPhase 2NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Sponsor: Peking University People's HospitalEnrolling: 501 location